- Home
- BCAB
BCAB
BioAtla Inc.
as 02-04-2025 2:31pm EST
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 28.6M | IPO Year: | 2020 |
| Target Price: | $5.00 | AVG Volume (30 days): | 990.6K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.42 - $4.02 | Next Earning Date: | 03-25-2025 |
| Revenue: | $11,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BioAtla Inc. News
BCAB Breaking Stock News: Dive into BCAB Ticker-Specific Updates for Smart Investing
Zacks
a month ago
BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know
MT Newswires
2 months ago
BioAtla Prices Registered Direct Offering of 9.7 Million Shares for Expected Gross Proceeds of $9.2 Million
GlobeNewswire
2 months ago
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
Simply Wall St.
2 months ago
Insiders Give Up US$66k As BioAtla Stock Drops To US$1.31
GlobeNewswire
2 months ago
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
GlobeNewswire
2 months ago
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
MT Newswires
3 months ago
HC Wainwright Downgrades BioAtla to Neutral From Buy
GuruFocus.com
3 months ago
BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Compare BCAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCAB BioAtla Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.